# NBE-002 in Patients With Advanced Solid Tumors

> **NCT04441099** · PHASE1,PHASE2 · TERMINATED · sponsor: **NBE-Therapeutics AG** · enrollment: 12 (actual)

## Conditions studied

- Advanced Solid Tumor
- Advanced Cancer
- Triple Negative Breast Cancer

## Interventions

- **DRUG:** NBE-002

## Key facts

- **NCT ID:** NCT04441099
- **Lead sponsor:** NBE-Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-19
- **Primary completion:** 2023-08-14
- **Final completion:** 2023-08-14
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** End of Program
- **Last updated:** 2023-09-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04441099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04441099, "NBE-002 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04441099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*